@article{SerenGrimmFitzetal.2016,
  author    = {Seren, {\"U}mit and Grimm, Dominik and Fitz, Joffrey and Weigel, Detlef and Nordborg, Magnus and Borgwardt, Karsten and Korte, Arthur},
  title     = {AraPheno: a public database for Arabidopsis thaliana phenotypes},
  series = {Nucleic Acids Research},
  volume    = {45},
  journal   = {Nucleic Acids Research},
  number    = {D1},
  doi       = {10.1093/nar/gkw986},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-147909},
  pages     = {D1054-D1059},
  year      = {2016},
  abstract  = {Natural genetic variation makes it possible to discover evolutionary changes that have been maintained in a population because they are advantageous. To understand genotype-phenotype relationships and to investigate trait architecture, the existence of both high-resolution genotypic and phenotypic data is necessary. Arabidopsis thaliana is a prime model for these purposes. This herb naturally occurs across much of the Eurasian continent and North America. Thus, it is exposed to a wide range of environmental factors and has been subject to natural selection under distinct conditions. Full genome sequencing data for more than 1000 different natural inbred lines are available, and this has encouraged the distributed generation of many types of phenotypic data. To leverage these data for meta analyses, AraPheno (https://arapheno.1001genomes.org) provide a central repository of population-scale phenotypes for A. thaliana inbred lines. AraPheno includes various features to easily access, download and visualize the phenotypic data. This will facilitate a comparative analysis of the many different types of phenotypic data, which is the base to further enhance our understanding of the genotype-phenotype map.},
  language  = {en}
}
@article{LendersWeidemannKurschatetal.2016,
  author    = {Lenders, Malte and Weidemann, Frank and Kurschat, Christine and Canaan-K{\"u}hl, Sima and Duning, Thomas and Stypmann, J{\"o}rg and Schmitz, Boris and Reiermann, Stefanie and Kr{\"a}mer, Johannes and Blaschke, Daniela and Wanner, Christoph and Brand, Stefan-Martin and Brand, Eva},
  title     = {Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant},
  series = {Orphanet Journal of Rare Diseases},
  volume    = {11},
  journal   = {Orphanet Journal of Rare Diseases},
  number    = {54},
  doi       = {10.1186/s13023-016-0441-z},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-166559},
  year      = {2016},
  abstract  = {Background Fabry disease (FD) is an X-linked multisystemic disorder with a heterogeneous phenotype. Especially atypical or late-onset type 2 phenotypes present a therapeutical dilemma. Methods To determine the clinical impact of the alpha-Galactosidase A (GLA) p.A143T/ c.427G > A variation, we retrospectively analyzed 25 p.A143T patients in comparison to 58 FD patients with other missense mutations. Results p.A143T patients suffering from stroke/ transient ischemic attacks had slightly decreased residual GLA activities, and/or increased lyso-Gb3 levels, suspecting FD. However, most male p.A143T patients presented with significant residual GLA activity (~50 \% of reference), which was associated with normal lyso-Gb3 levels. Additionally, p.A143T patients showed less severe FD-typical symptoms and absent FD-typical renal and cardiac involvement in comparison to FD patients with other missense mutations. Two tested female p.A143T patients with stroke/TIA did not show skewed X chromosome inactivation. No accumulation of neurologic events in family members of p.A143T patients with stroke/transient ischemic attacks was observed. Conclusions We conclude that GLA p.A143T seems to be most likely a neutral variant or a possible modifier instead of a disease-causing mutation. Therefore, we suggest that p.A143T patients with stroke/transient ischemic attacks of unknown etiology should be further evaluated, since the diagnosis of FD is not probable and subsequent ERT or chaperone treatment should not be an unreflected option.},
  language  = {en}
}